lixivaptan has been researched along with Polycystic Kidney, Autosomal Dominant in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Di Mise, A; Pellegrini, L; Torres, VE; Valenti, G; Wang, X; Ye, H | 1 |
| Howell, BA; Pellegrini, L; Shoda, LKM; Woodhead, JL | 1 |
| Chebib, FT; Constans, MM; Pellegrini, L; Torres, VE; Wang, X | 1 |
3 other study(ies) available for lixivaptan and Polycystic Kidney, Autosomal Dominant
| Article | Year |
|---|---|
Pre-clinical evaluation of dual targeting of the GPCRs CaSR and V2R as therapeutic strategy for autosomal dominant polycystic kidney disease.
Topics: Animals; Benzamides; Cyclic AMP; Drug Therapy, Combination; Female; Male; Mice; Mice, Inbred C57BL; Phenethylamines; Polycystic Kidney, Autosomal Dominant; Propylamines; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Calcium-Sensing; Receptors, Vasopressin | 2021 |
Comparison of the Hepatotoxic Potential of Two Treatments for Autosomal-Dominant Polycystic Kidney DiseaseUsing Quantitative Systems Toxicology Modeling.
Topics: Benzamides; Chemical and Drug Induced Liver Injury; Drug-Related Side Effects and Adverse Reactions; Humans; Models, Theoretical; Polycystic Kidney, Autosomal Dominant; Pyrroles; Tolvaptan | 2020 |
Effect of a Vasopressin V2 Receptor Antagonist on Polycystic Kidney Disease Development in a Rat Model.
Topics: Administration, Oral; Animals; Antidiuretic Hormone Receptor Antagonists; Benzamides; Creatinine; Cysts; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Kidney; Liver; Liver Diseases; Mutation; Organ Size; Polycystic Kidney, Autosomal Dominant; Pyrroles; Rats; Receptors, Cell Surface; Receptors, Vasopressin | 2019 |